1. Home
  2. CANF vs LYRA Comparison

CANF vs LYRA Comparison

Compare CANF & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CANF
  • LYRA
  • Stock Information
  • Founded
  • CANF 1994
  • LYRA 2005
  • Country
  • CANF Israel
  • LYRA United States
  • Employees
  • CANF N/A
  • LYRA N/A
  • Industry
  • CANF Biotechnology: Pharmaceutical Preparations
  • LYRA Medical/Dental Instruments
  • Sector
  • CANF Health Care
  • LYRA Health Care
  • Exchange
  • CANF Nasdaq
  • LYRA Nasdaq
  • Market Cap
  • CANF 13.5M
  • LYRA 15.0M
  • IPO Year
  • CANF N/A
  • LYRA 2020
  • Fundamental
  • Price
  • CANF $0.66
  • LYRA $6.58
  • Analyst Decision
  • CANF Strong Buy
  • LYRA Buy
  • Analyst Count
  • CANF 2
  • LYRA 2
  • Target Price
  • CANF $14.00
  • LYRA $16.00
  • AVG Volume (30 Days)
  • CANF 314.0K
  • LYRA 37.8K
  • Earning Date
  • CANF 08-29-2025
  • LYRA 08-13-2025
  • Dividend Yield
  • CANF N/A
  • LYRA N/A
  • EPS Growth
  • CANF N/A
  • LYRA N/A
  • EPS
  • CANF N/A
  • LYRA N/A
  • Revenue
  • CANF $674,000.00
  • LYRA $1,185,000.00
  • Revenue This Year
  • CANF $461.72
  • LYRA N/A
  • Revenue Next Year
  • CANF N/A
  • LYRA $139.18
  • P/E Ratio
  • CANF N/A
  • LYRA N/A
  • Revenue Growth
  • CANF N/A
  • LYRA N/A
  • 52 Week Low
  • CANF $0.63
  • LYRA $3.81
  • 52 Week High
  • CANF $3.24
  • LYRA $37.50
  • Technical
  • Relative Strength Index (RSI)
  • CANF 12.02
  • LYRA 33.89
  • Support Level
  • CANF $1.00
  • LYRA $7.77
  • Resistance Level
  • CANF $1.05
  • LYRA $8.37
  • Average True Range (ATR)
  • CANF 0.05
  • LYRA 0.54
  • MACD
  • CANF -0.04
  • LYRA -0.10
  • Stochastic Oscillator
  • CANF 5.86
  • LYRA 10.48

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: